The composition and distribution of Insulin-like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients

Effects of IGF-I therapy on IGFBP-3

S. E. Gargosky, K. F. Wilson, P. J. Fielder, M. A. Vaccarello, J. Guevara-Aguirre, F. B. Diamond, R. C. Baxter, A. L. Rosenbloom, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We have previously reported that adult GH receptor-deficient (GHRD) patients treated subcutaneously with recombinant human insulin-like growth factor (IGF)-I have increased serum IGF-I levels and decreased IGF-II levels, whereas IGF-binding protein-3 (IGFBP-3) levels were unchanged. To further investigate the effects of IGF-I administration upon the IGF-IGFBP axis in GHRD, we have examined: 1) the molecular distribution of IGF-I and IGF-II among the IGFBPs; 2) the composition and distribution of the IGFBPs, in particular IGFBP-3; and 3) the acid labile subunit (ALS). Serum samples from adult GHRD patients who were treated sc with recombinant human IGF-I (40 μg/kg, sc, twice a day) or from normal Ecuadorian adults were incubated with [125I]IGF-II and subjected to neutral size-exclusion chromatography. The fractions were then subjected to Western ligand blot, Western immunoblot, IGFBP-3 RIA, and IGF RIAs. Serum of healthy adults incorporated [125I]IGF-II into the 150- and 44-kilodalton (kDa) IGFBP region. The 150-kDa IGFBP region contained most of the circulating IGFBP-3, whereas the 44-kDa IGFBP region contained mainly IGFBP-1, 2, and 4. The 150-kDa region also contained a unique 28-kDa immunoreactive form of IGFBP-3, which was not detectable by Western ligand blot. Endogenous IGF-I and IGF-II were distributed equally in the 150- and 44-kDa IGFBP regions. Sera from GHRD patients mainly incorporated [125I]IGF-II into the 44-kDa IGFBP region. Similar to control sera, the 150-kDa IGFBP region contained IGFBP-3, albeit at lower concentrations. The 44-kDa IGFBP region contained all IGFBPs including 50% of the total immunoreactive IGFBP-3. The two immunoreactive forms of IGFBP 3 (40- to 45-kDa doublet and 28-kDa band) were present in both IGFBP regions. The IGF size-distribution study revealed that the 150-kDa IGFBP region carried half of the circulating endogenous IGF-I, but only 30% of the IGF-II. Concentrations of the ALS were consistently low. Administration of IGF-I to GHRD patients was unable to increase concentrations of the molecular forms of IGFBP-3, correct the aberrant distribution of IGFs among the IGFBPs, or increase serum concentrations of ALS. In conclusion, we have found two forms of IGFBP-3 associated with IGF and ALS, which are capable of forming the ternary 150-kDa complex in healthy adult serum. The ratio of these two forms of IGFBP-3 and their distribution in serum was different between GHRD and control patients. These data may provide an explanation for the altered IGF distribution also observed in GHRD patients. Furthermore, we have found that the administration of IGF-I to patients with GHRD failed to elevate total IGF levels or to increase IGFBP-3 or ALS levels in the circulation.

Original languageEnglish (US)
Pages (from-to)1683-1689
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume77
Issue number6
StatePublished - Dec 1993
Externally publishedYes

Fingerprint

Somatotropin Receptors
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor Binding Protein 3
Somatomedins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Serum
Chemical analysis
Therapeutics
Acids
Western Blotting
Insulin-Like Growth Factor Binding Protein 4
Ligands
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 2
Size exclusion chromatography

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

The composition and distribution of Insulin-like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients : Effects of IGF-I therapy on IGFBP-3. / Gargosky, S. E.; Wilson, K. F.; Fielder, P. J.; Vaccarello, M. A.; Guevara-Aguirre, J.; Diamond, F. B.; Baxter, R. C.; Rosenbloom, A. L.; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 6, 12.1993, p. 1683-1689.

Research output: Contribution to journalArticle

Gargosky, SE, Wilson, KF, Fielder, PJ, Vaccarello, MA, Guevara-Aguirre, J, Diamond, FB, Baxter, RC, Rosenbloom, AL & Rosenfeld, RR 1993, 'The composition and distribution of Insulin-like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: Effects of IGF-I therapy on IGFBP-3', Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 6, pp. 1683-1689.
Gargosky, S. E. ; Wilson, K. F. ; Fielder, P. J. ; Vaccarello, M. A. ; Guevara-Aguirre, J. ; Diamond, F. B. ; Baxter, R. C. ; Rosenbloom, A. L. ; Rosenfeld, Ronald (Ron). / The composition and distribution of Insulin-like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients : Effects of IGF-I therapy on IGFBP-3. In: Journal of Clinical Endocrinology and Metabolism. 1993 ; Vol. 77, No. 6. pp. 1683-1689.
@article{c6399be43f0542659b52e5a7b82f1b66,
title = "The composition and distribution of Insulin-like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: Effects of IGF-I therapy on IGFBP-3",
abstract = "We have previously reported that adult GH receptor-deficient (GHRD) patients treated subcutaneously with recombinant human insulin-like growth factor (IGF)-I have increased serum IGF-I levels and decreased IGF-II levels, whereas IGF-binding protein-3 (IGFBP-3) levels were unchanged. To further investigate the effects of IGF-I administration upon the IGF-IGFBP axis in GHRD, we have examined: 1) the molecular distribution of IGF-I and IGF-II among the IGFBPs; 2) the composition and distribution of the IGFBPs, in particular IGFBP-3; and 3) the acid labile subunit (ALS). Serum samples from adult GHRD patients who were treated sc with recombinant human IGF-I (40 μg/kg, sc, twice a day) or from normal Ecuadorian adults were incubated with [125I]IGF-II and subjected to neutral size-exclusion chromatography. The fractions were then subjected to Western ligand blot, Western immunoblot, IGFBP-3 RIA, and IGF RIAs. Serum of healthy adults incorporated [125I]IGF-II into the 150- and 44-kilodalton (kDa) IGFBP region. The 150-kDa IGFBP region contained most of the circulating IGFBP-3, whereas the 44-kDa IGFBP region contained mainly IGFBP-1, 2, and 4. The 150-kDa region also contained a unique 28-kDa immunoreactive form of IGFBP-3, which was not detectable by Western ligand blot. Endogenous IGF-I and IGF-II were distributed equally in the 150- and 44-kDa IGFBP regions. Sera from GHRD patients mainly incorporated [125I]IGF-II into the 44-kDa IGFBP region. Similar to control sera, the 150-kDa IGFBP region contained IGFBP-3, albeit at lower concentrations. The 44-kDa IGFBP region contained all IGFBPs including 50{\%} of the total immunoreactive IGFBP-3. The two immunoreactive forms of IGFBP 3 (40- to 45-kDa doublet and 28-kDa band) were present in both IGFBP regions. The IGF size-distribution study revealed that the 150-kDa IGFBP region carried half of the circulating endogenous IGF-I, but only 30{\%} of the IGF-II. Concentrations of the ALS were consistently low. Administration of IGF-I to GHRD patients was unable to increase concentrations of the molecular forms of IGFBP-3, correct the aberrant distribution of IGFs among the IGFBPs, or increase serum concentrations of ALS. In conclusion, we have found two forms of IGFBP-3 associated with IGF and ALS, which are capable of forming the ternary 150-kDa complex in healthy adult serum. The ratio of these two forms of IGFBP-3 and their distribution in serum was different between GHRD and control patients. These data may provide an explanation for the altered IGF distribution also observed in GHRD patients. Furthermore, we have found that the administration of IGF-I to patients with GHRD failed to elevate total IGF levels or to increase IGFBP-3 or ALS levels in the circulation.",
author = "Gargosky, {S. E.} and Wilson, {K. F.} and Fielder, {P. J.} and Vaccarello, {M. A.} and J. Guevara-Aguirre and Diamond, {F. B.} and Baxter, {R. C.} and Rosenbloom, {A. L.} and Rosenfeld, {Ronald (Ron)}",
year = "1993",
month = "12",
language = "English (US)",
volume = "77",
pages = "1683--1689",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - The composition and distribution of Insulin-like Growth Factors (IGFs) and IGF-Binding Proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients

T2 - Effects of IGF-I therapy on IGFBP-3

AU - Gargosky, S. E.

AU - Wilson, K. F.

AU - Fielder, P. J.

AU - Vaccarello, M. A.

AU - Guevara-Aguirre, J.

AU - Diamond, F. B.

AU - Baxter, R. C.

AU - Rosenbloom, A. L.

AU - Rosenfeld, Ronald (Ron)

PY - 1993/12

Y1 - 1993/12

N2 - We have previously reported that adult GH receptor-deficient (GHRD) patients treated subcutaneously with recombinant human insulin-like growth factor (IGF)-I have increased serum IGF-I levels and decreased IGF-II levels, whereas IGF-binding protein-3 (IGFBP-3) levels were unchanged. To further investigate the effects of IGF-I administration upon the IGF-IGFBP axis in GHRD, we have examined: 1) the molecular distribution of IGF-I and IGF-II among the IGFBPs; 2) the composition and distribution of the IGFBPs, in particular IGFBP-3; and 3) the acid labile subunit (ALS). Serum samples from adult GHRD patients who were treated sc with recombinant human IGF-I (40 μg/kg, sc, twice a day) or from normal Ecuadorian adults were incubated with [125I]IGF-II and subjected to neutral size-exclusion chromatography. The fractions were then subjected to Western ligand blot, Western immunoblot, IGFBP-3 RIA, and IGF RIAs. Serum of healthy adults incorporated [125I]IGF-II into the 150- and 44-kilodalton (kDa) IGFBP region. The 150-kDa IGFBP region contained most of the circulating IGFBP-3, whereas the 44-kDa IGFBP region contained mainly IGFBP-1, 2, and 4. The 150-kDa region also contained a unique 28-kDa immunoreactive form of IGFBP-3, which was not detectable by Western ligand blot. Endogenous IGF-I and IGF-II were distributed equally in the 150- and 44-kDa IGFBP regions. Sera from GHRD patients mainly incorporated [125I]IGF-II into the 44-kDa IGFBP region. Similar to control sera, the 150-kDa IGFBP region contained IGFBP-3, albeit at lower concentrations. The 44-kDa IGFBP region contained all IGFBPs including 50% of the total immunoreactive IGFBP-3. The two immunoreactive forms of IGFBP 3 (40- to 45-kDa doublet and 28-kDa band) were present in both IGFBP regions. The IGF size-distribution study revealed that the 150-kDa IGFBP region carried half of the circulating endogenous IGF-I, but only 30% of the IGF-II. Concentrations of the ALS were consistently low. Administration of IGF-I to GHRD patients was unable to increase concentrations of the molecular forms of IGFBP-3, correct the aberrant distribution of IGFs among the IGFBPs, or increase serum concentrations of ALS. In conclusion, we have found two forms of IGFBP-3 associated with IGF and ALS, which are capable of forming the ternary 150-kDa complex in healthy adult serum. The ratio of these two forms of IGFBP-3 and their distribution in serum was different between GHRD and control patients. These data may provide an explanation for the altered IGF distribution also observed in GHRD patients. Furthermore, we have found that the administration of IGF-I to patients with GHRD failed to elevate total IGF levels or to increase IGFBP-3 or ALS levels in the circulation.

AB - We have previously reported that adult GH receptor-deficient (GHRD) patients treated subcutaneously with recombinant human insulin-like growth factor (IGF)-I have increased serum IGF-I levels and decreased IGF-II levels, whereas IGF-binding protein-3 (IGFBP-3) levels were unchanged. To further investigate the effects of IGF-I administration upon the IGF-IGFBP axis in GHRD, we have examined: 1) the molecular distribution of IGF-I and IGF-II among the IGFBPs; 2) the composition and distribution of the IGFBPs, in particular IGFBP-3; and 3) the acid labile subunit (ALS). Serum samples from adult GHRD patients who were treated sc with recombinant human IGF-I (40 μg/kg, sc, twice a day) or from normal Ecuadorian adults were incubated with [125I]IGF-II and subjected to neutral size-exclusion chromatography. The fractions were then subjected to Western ligand blot, Western immunoblot, IGFBP-3 RIA, and IGF RIAs. Serum of healthy adults incorporated [125I]IGF-II into the 150- and 44-kilodalton (kDa) IGFBP region. The 150-kDa IGFBP region contained most of the circulating IGFBP-3, whereas the 44-kDa IGFBP region contained mainly IGFBP-1, 2, and 4. The 150-kDa region also contained a unique 28-kDa immunoreactive form of IGFBP-3, which was not detectable by Western ligand blot. Endogenous IGF-I and IGF-II were distributed equally in the 150- and 44-kDa IGFBP regions. Sera from GHRD patients mainly incorporated [125I]IGF-II into the 44-kDa IGFBP region. Similar to control sera, the 150-kDa IGFBP region contained IGFBP-3, albeit at lower concentrations. The 44-kDa IGFBP region contained all IGFBPs including 50% of the total immunoreactive IGFBP-3. The two immunoreactive forms of IGFBP 3 (40- to 45-kDa doublet and 28-kDa band) were present in both IGFBP regions. The IGF size-distribution study revealed that the 150-kDa IGFBP region carried half of the circulating endogenous IGF-I, but only 30% of the IGF-II. Concentrations of the ALS were consistently low. Administration of IGF-I to GHRD patients was unable to increase concentrations of the molecular forms of IGFBP-3, correct the aberrant distribution of IGFs among the IGFBPs, or increase serum concentrations of ALS. In conclusion, we have found two forms of IGFBP-3 associated with IGF and ALS, which are capable of forming the ternary 150-kDa complex in healthy adult serum. The ratio of these two forms of IGFBP-3 and their distribution in serum was different between GHRD and control patients. These data may provide an explanation for the altered IGF distribution also observed in GHRD patients. Furthermore, we have found that the administration of IGF-I to patients with GHRD failed to elevate total IGF levels or to increase IGFBP-3 or ALS levels in the circulation.

UR - http://www.scopus.com/inward/record.url?scp=0027131718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027131718&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 1683

EP - 1689

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -